Emerging drugs for the treatment of tobacco dependence: 2014 update

Expert Opinion on Emerging Drugs

Volumn 19, Issue 2, 2014, Pages 243-260

  Elrashidi, Muhamad Y ^a   Ebbert, Jon O ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atomoxetine; Baclofen; Bupropion; Buspirone; Carvedilol; Clonidine; Cytisine; D cycloserine; Emerging pharmacotherapies; EVT 302; GSK598809; Labetalol; Lobeline; Mecamylamine; N acetylcysteine; Naltrexone; Nicotine replacement therapy

Indexed keywords

ACETATE SILVER; AMFEBUTAMONE; ATOMOXETINE; BACLOFEN; BUSPIRONE; CARVEDILOL; CLONIDINE; CYCLOSERINE; CYTISINE; DSB GSK 598809; GSK 598809; LABETALOL; LOBELINE; MECAMYLAMINE; NALTREXONE; NICOBREVIN; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NORTRIPTYLINE; PLACEBO; REBOXETINE; RIMONABANT; SELEGILINE; SILVER; SURINABANT; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; VIGABATRIN; BENZAZEPINE DERIVATIVE; PROPYLAMINE; QUINOXALINE DERIVATIVE;

CONSTIPATION; DECREASED APPETITE; DIZZINESS; DROWSINESS; GASTROINTESTINAL SYMPTOM; HICCUP; HUMAN; INSOMNIA; MOUTH ULCER; NAUSEA; NICOTINE REPLACEMENT THERAPY; PRESCRIPTION; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE; TOBACCO USE; WITHDRAWAL SYNDROME; XEROSTOMIA; CLINICAL TRIAL (TOPIC); TOBACCO USE DISORDER;

BENZAZEPINES; BUPROPION; CLINICAL TRIALS AS TOPIC; CLONIDINE; HUMANS; MECAMYLAMINE; NICOTINE; NORTRIPTYLINE; PROPYLAMINES; QUINOXALINES; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER;

EID: 84901287627     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.899580     Document Type: Review

References (159)

1. King B. Vital signs: Current cigarette smoking among adults aged >/=18 years-United States, 2005-2010. MMWR Morb Mortal Wkly Rep 2011;60:1207-12
2. World Health Organization. WHO report on the global tobacco epidemic, 2011. warning about the dangers of tobacco. World Health Organization; Geneva, Switzerland: 2011
3. Giovino GA, Mirza SA, Samet JM, et al. Tobacco use in 3 billion individuals from 16 countries: An analysis of nationally representative cross-sectional household surveys. Lancet 2012;380:668-79
4. U.S. Department of Health and Human Services. How tobacco smoke causes disease: The biology and behavioral basis for smoking-Attributable disease: A report of the surgeon general. Department of health and human services, centers for disease control and prevention, national center for chronic disease prevention and health promotion, office on smoking and health; Atlanta GA, USA; 2010
5. U.S. Department of Health and Human Services. The health consequences of smoking-50 years of progress: A report of the surgeon general. Department of health and human services, centers for disease control and prevention, national center for chronic disease prevention and health promotion, office on smoking and health; Atlanta GA, USA; 2014
6. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-Century hazards of smoking and benefits of cessation in the united states. N Engl J Med 2013;368:341-50
7. Centers for Disease Control and Prevention. Smoking-Attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008;57:1226-8
8. Centers for Disease Control and Prevention. CDC fact sheet: Smoking & tobacco use. 2012. Available from: Http://www.cdc.gov/tobacco/data-statistics/ fact-sheets/fast-facts/#cost [Last Accessed 30 January 2014]
9. World Lung Foundation. New tobacco atlas estimates U.S. $35 billion tobacco industry profits and almost 6 million annual deaths. 2012. Available from: Http://www.worldlungfoundation.org/ht/display/ReleaseDetails/i/ 20439/pid/6858 [Last Accessed 22 November 2013]
10. Richard P, West K, Ku L. The return on investment of a Medicaid tobacco cessation program in Massachusetts. PLoS One 2012;7:e29665
11. Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: A review. Int J Tuberc Lung Dis 2003;7:811-19 (Pubitemid 37158418
12. Benowitz NL. Nicotine addiction. N Engl J Med 2010;362:2295-303
13. Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 1995;117:2-10; discussion 4-20
14. Benowitz NL. Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71
15. Brennan KA, Putt F, Truman P. Nicotine-, tobacco particulate matterand methamphetamine-produced locomotor sensitisation in rats. Psychopharmacology (Berl) 2013;228:659-72
16. Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: Bridging the gap from molecules to behaviour. Nat Rev Neurosci 2004;5:55-65 (Pubitemid 38076184
17. Leslie FM, Mojica CY, Reynaga DD. Nicotinic receptors in addiction pathways. Mol Pharmacol 2013;83:753-8
18. Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and Dependence: 2008 Update. 2008. Available from: Http://www.ncbi.nlm.nih.gov/ books/NBK63952/ [Last Accessed 22 November 2013]
19. Hughes Jr. Motivating and helping smokers to stop smoking. J Gen Intern Med 2003;18:1053-7 (Pubitemid 38091401
20. Cohen S, Lichtenstein E, Prochaska JO, et al. Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol 1989;44:1355-65
21. Agaku IT, King BA, Dube SR. Current cigarette smoking among adults-united states, 2005-2012. MMWR Morb Mortal Wkly Rep 2014;63:29-34
22. U.S. Department of Health and Human Services. Preventing tobacco use among youth and young adults: A report of the surgeon general. Department of health and human services, centers for disease control and prevention, national center for chronic disease prevention and health promotion, office on smoking and health, Atlanta GA, US; 2012
23. Kendler KS, Myers J, Damaj MI, Chen X. Early smoking onset and risk for subsequent nicotine dependence: A monozygotic co-Twin control study. Am J Psychiatry 2013;170:408-13
24. American Cancer Society. Guide to quitting smoking. 2013. Available from: Http://www.cancer.org/healthy/stayawayfromtobacco/guidetoquittingsmoking/guide- Toquitting-smoking-benefits [Last Accessed 16 February 2014]
25. Centers for Disease Control and Prevention. Quitting smoking among adults-united states, 2001-2010. MMWR Morb Mortal Wkly Rep 2011;60:1513-19
26. Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007;6:746-62 (Pubitemid 47338182
27. Conklin CA, Perkins KA, Sheidow AJ, et al. The return to smoking: 1-year relapse trajectories among female smokers. Nicotine Tob Res 2005;7:533-40 (Pubitemid 41600911
28. Fu SS, Partin MR, Snyder A, et al. Promoting repeat tobacco dependence treatment: Are relapsed smokers interested?. Am J Manag Care 2006;12:235-43
29. Sims TH, Fiore MC. Pharmacotherapy for treating tobacco dependence: What is the ideal duration of therapy?. CNS Drugs 2002;16:653-62
30. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010;70:2357-72
31. Sabaté E, editor. Adherence to long-Term therapies: Evidence for action Chapter XIV. World Health Organization; Geneva, Switzerland; 2003
32. Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherence. Nicotine Tob Res 2010;12:574-81
33. Zeng F, Chen CI, Mastey V, et al. Effects of copayment on initiation of smoking cessation pharmacotherapy: An analysis of varenicline reversed claims. Clin Ther 2011;33:225-34
34. Liberman JN, Lichtenfeld MJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm 2013;19:125-31
35. Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2002;346:506-12 (Pubitemid 34441743
36. Abrams DB, Graham AL, Levy DT, et al. Boosting population quits through evidence-based cessation treatment and policy. Am J Prev Med 2010;38:S351-S63
37. Gollust SE, Schroeder SA, Warner KE. Helping smokers quit: Understanding the barriers to utilization of smoking cessation services. Milbank Q 2008;86:601-27
38. Reda AA, Kaper J, Fikrelter H, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev 2009(2):CD004305
39. Wray JM, Gass JC, Tiffany ST. A systematic review of the relationships between craving and smoking cessation. Nicotine Tob Res 2013;15:1167-82
40. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012(11):CD000146
41. West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl) 2001;153:225-30 (Pubitemid 32127891
42. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: Clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet 2001;40:661-84 (Pubitemid 32954989
43. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999;281:72-6 (Pubitemid 29025103
44. Tonnesen P, Lauri H, Perfekt R, et al. Efficacy of a nicotine mouth spray in smoking cessation: A randomised, doubleblind trial. Eur Respir J 2012;40:548-54
45. Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 2004;99:83-92 (Pubitemid 38142226
46. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003;5:635-44
47. Ebbert JO. Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use. Evid Based Med 2013;18:212-13
48. Carpenter MJ, Jardin BF, Burris JL, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: A review of the literature. Drugs 2013;73:407-26
49. US Department of Health and Human Services. US food and drug administration. Nicotine replacement therapy labels may change. FDA Consumer Health Information. 2013.Available from: Http://www.fda.gov/ForConsumers/ ConsumerUpdates/ucm345087.htm [Last Accessed 18 February 2014]
50. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustainedrelease combination therapy for smoking cessation. Nicotine Tob Res 2009;11:234-9
51. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202 (Pubitemid 27454451
52. McCarthy DE, Piasecki TM, Lawrence DL, et al. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction 2008;103:1521-33
53. Kotlyar M, Drone D, Thuras P, et al. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine Tob Res 2011;13:492-7
54. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: An overview and network meta-Analysis. Cochrane Database Syst Rev 2013(5):CD009329
55. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007(1):CD000031
56. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012(1):CD006219
57. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013(2):CD007253
58. Burke MV, Ebbert JO, Hays JT. Treatment of tobacco dependence. Mayo Clin Proc 2008;83:479-83; quiz 83-4
59. Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: A network meta-Analysis. Circulation 2014;129:28-41
60. The FDA approves new drug for smoking cessation. FDA Consum 2006;40:29
61. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7 (Pubitemid 40664098
62. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008;359:2018-24
63. Ebbert JO. Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs 2009;14:23-32
64. Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009;11:572-6
65. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone?. A randomised controlled trial. BMC Med 2013;11:140
66. Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion sr for tobacco-dependence treatment in cigarette smokers: A randomized trial. JAMA 2014;311:155-63
67. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 2006;296:64-71
68. Jimenez-Ruiz CA, Barrios M, Pena S, et al. Increasing the dose of varenicline in patients who do not respond to the standard dose. Mayo Clin Proc 2013;88:1443-5
69. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012(4):CD006103
70. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006;296:56-63
71. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006;296:47-55
72. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 2008;299:1121-2 (Pubitemid 351398444
73. Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev 2003;9:327-42 (Pubitemid 38031862
74. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-9 (Pubitemid 20303384
75. Breslau N, Peterson EL, Schultz LR, et al. Major depression and stages of smoking: A longitudinal investigation. Arch Gen Psychiatry 1998;55:161-6 (Pubitemid 28087602
76. Weinberger AH, Mazure CM, Morlett A, McKee SA. Two decades of smoking cessation treatment research on smokers with depression: 1990-2010. Nicotine Tob Res 2013;15:1014-31
77. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: A review. Nicotine Tob Res 2005;7:491-9
78. Quaak M, van Schayck CP, Postma DS, et al. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012;107:178-87
79. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004(3):CD000058
80. Gehricke JG, Hong N, Wigal TL, et al. ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav 2011;98:485-91
81. Silverstone PH, Dadashova R. Atomoxetine treatment for nicotine withdrawal: A pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. Ann Gen Psychiatry 2012;11:6
82. Sacco KA, Creeden C, Reutenauer EL, et al. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res 2009;107:332-3
83. Dadashova R, Silverstone P. Off-label use of atomoxetine in adults: Is it safe?. Mental Illness 2012;4:e19
84. Cousins MS, Stamat HM, de Wit H. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 2001;3:123-9 (Pubitemid 32621773
85. Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebocontrolled smoking reduction study. Drug Alcohol Depend 2009;103:30-6
86. Sofuoglu M, Babb D, Hatsukami DK. Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res 2003;5:947-53 (Pubitemid 38029091
87. Sofuoglu M, Mouratidis M, Yoo S, Kosten T. Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. Behav Pharmacol 2006;17:731-5
88. Stead LF, Hughes Jr. Lobeline for smoking cessation. Cochrane Database Syst Rev 2012(2):CD000124
89. Glover ED, Rath JM, Sharma E, et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation. Am J Health Behav 2010;34:101-9
90. McKee SA, Weinberger AH, Harrison EL, et al. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: A preliminary study. Schizophr Res 2009;115:317-24
91. Glover ED, Laflin MT, Schuh KJ, et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 2007;102:795-802 (Pubitemid 46633360
92. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev 2000(2):CD001009
93. Wong GY, Wolter TD, Croghan GA, et al. A randomized trial of naltrexone for smoking cessation. Addiction 1999;94:1227-37 (Pubitemid 29385151
94. Hadjiconstantinou M, Neff NH. Nicotine and endogenous opioids: Neurochemical and pharmacological evidence. Neuropharmacology 2011;60:1209-20
95. Berrendero F, Robledo P, Trigo JM, et al. Neurobiological mechanisms involved in nicotine dependence and reward: Participation of the endogenous opioid system. Neurosci Biobehav Rev 2010;35:220-31
96. David SP, Lancaster T, Stead LF, et al. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2013(6):CD003086
97. King A, de Wit H, Riley RC, et al. Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine Tob Res 2006;8:671-82
98. Walsh Z, Epstein A, Munisamy G, King A. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis 2008;27:65-72
99. Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: Past, present and future. Drug Alcohol Rev 2006;25:59-71 (Pubitemid 43308154
100. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: Systematic review and meta-Analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737
101. Szalavitz M. How a study of a failed antidepressant shows that antidepressants really work. Time October 18, 2010
102. Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011(3):CD005353
103. Merritt LL, Martin BR, Walters C, et al. The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 2008;326:483-92
104. Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: Pilot data. J Investig Med 2011;59:1280-3
105. Tonstad S, Aubin HJ. Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: A randomized controlled clinical trial. J Psychopharmacol 2012;26:1003-9
106. Killen JD, Fortmann SP, Murphy GM Jr, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction 2010;105:1660-8
107. Houtsmuller EJ, Thornton JA, Stitzer ML. Effects of selegiline (L-deprenyl) during smoking and short-Term abstinence. Psychopharmacology (Berl) 2002;163:213-20 (Pubitemid 35013613
108. George TP, Vessicchio JC, Termine A, et al. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003;53:136-43 (Pubitemid 36126476
109. Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003;98:1403-7 (Pubitemid 37297247
110. Kahn R, Gorgon L, Jones K, et al. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res 2012;14:377-82
111. Weinberger AH, Reutenauer EL, Jatlow PI, et al. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 2010;107:188-95
112. Syed BA, Chaudhari K. Smoking cessation drugs market. Nat Rev Drug Discov 2013;12:97-8
113. Sofuoglu M, Mouratidis M, Yoo S, et al. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2005;181:504-10 (Pubitemid 41480899
114. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: A critical review of the literature. J Clin Psychiatry 2010;71:634-48
115. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012;100:801-10
116. Khazaal Y, Cornuz J, Bilancioni R, Zullino DF. Topiramate for smoking cessation. Psychiatry Clin Neurosci 2006;60:384-8 (Pubitemid 43736406
117. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial. Arch Intern Med 2005;165:1600-5 (Pubitemid 41124153
118. Reid MS, Palamar J, Raghavan S, Flammino F. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology (Berl) 2007;192:147-58 (Pubitemid 46673896
119. Sofuoglu M, Poling J, Mouratidis M, Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2006;184:645-51 (Pubitemid 43255881
120. Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 2008;103:687-94 (Pubitemid 351389286
121. Baltieri DA, Daro FR, Ribeiro PL, Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend 2009;105:33-41
122. Weinberger AH, George TP, Perkins KA, Chengappa KN. Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type. J Clin Psychopharmacol 2008;28:247-8 (Pubitemid 351417137
123. Khazaal Y, Zullino DF. Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-Triggered automatisms. J Clin Psychopharmacol 2009;29:192-3; author reply 3-4
124. Markou A, Paterson NE, Semenova S. Role of gamma-Aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: Potential pharmacotherapies for smoking cessation. Ann NY Acad Sci 2004;1025:491-503 (Pubitemid 39643899
125. Wickelgren I. Drug may suppress the craving for nicotine. Science 1998;282:1797-9
126. Etter JF. Cytisine for smoking cessation: A literature review and a meta-Analysis. Arch Intern Med 2006;166:1553-9
127. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: Systematic review and meta-Analysis. Thorax 2013;68:1037-42
128. Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ 2013;347:f5198
129. Aveyard P, West R. Cytisine and the failure to market and regulate for human health. Thorax 2013;68:989
130. Vinnikov D, Brimkulov N, Burjubaeva A. A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat 2008;3:57-62
131. West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193-200
132. Stapleton JA. The case for licensing cytosine now for smoking cessation is overwhelming. BMJ 2013;347:f5736
133. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Syst Rev 2012(9):CD000191
134. Rose JE, Behm FM, Murugesan T, McClernon FJ. Silver acetate interactions with nicotine and non-nicotine smoke components. Exp Clin Psychopharmacol 2010;18:462-9
135. Stead LF, Lancaster T. Nicobrevin for smoking cessation. Cochrane Database Syst Rev 2006(2):CD005990
136. Medicines and Healthcare Products Regulatory Agency. Drug Safety Update. Nicobrevin antismoking preparation: Withdrawn from the market. 2011. Available from: Http://www.mhra. gov.uk/Safetyinformation/DrugSafetyUpdate/CON117324 [Last Accessed 18 February 2014]
137. Hughes JR, Stead LF, Lancaster T. Anxiolytics and antidepressants for smoking cessation. Cochrane Database Syst Rev 2000(2):CD000031
138. Cinciripini PM, Lapitsky L, Seay S, et al. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: Differences between high-And low-Anxiety smokers. J Clin Psychopharmacol 1995;15:182-91
139. Schneider NG, Olmstead RE, Steinberg C, et al. Efficacy of buspirone in smoking cessation: A placebocontrolled trial. Clin Pharmacol Ther 1996;60:568-75 (Pubitemid 26414093
140. Santa Ana EJ, Rounsaville BJ, Frankforter TL, et al. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: A pilot investigation. Drug Alcohol Depend 2009;104:220-7
141. Yoon JH, Newton TF, Haile CN, et al. Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine-And nicotinedependent volunteers. Addict Behav 2013;38:1518-26
142. Mugnaini M, Iavarone L, Cavallini P, et al. Occupancy of brain dopamine d3 receptors and drug craving: A translational approach. Neuropsychopharmacology 2013;38:302-12
143. European College of Neuropsychopharmacology. ECNP Medicines Chest-List of Drugs. 2013.Available from: Http://www.ecnp. eu/projects-initiatives/ECNP- medicineschest/List-of-drugs.aspx [Last Accessed 20 December 2013]
144. Schmaal L, Berk L, Hulstijn KP, et al. Efficacy of N-Acetylcysteine in the treatment of nicotine dependence: A double-blind placebo-controlled pilot study. Eur Addict Res 2011;17:211-16
145. Knackstedt LA, LaRowe S, Mardikian P, et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009;65:841-5
146. Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains-in our lifetime. Am J Prev Med 2007;33:S340-8
147. Euromonitor International. NRT Smoking Cessation Aids in the US: Executive Summary. 2013.Available from: Http://www. euromonitor.com/nrt-smoking- cessationaids-in-The-us/report [Last Accessed 22 November 2013]
148. Hubbard R, Lewis S, West J, et al. Bupropion and the risk of sudden death: A self-controlled case-series analysis using the health improvement network. Thorax 2005;60:848-50 (Pubitemid 41475213
149. Ferry LH. The power of the press in smokers' attempts to quit. BMJ 2002;324:1346-7
150. Centers for Disease Control and Prevention. State medicaid coverage for tobacco-dependence treatments-United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1340-3
151. Turner JR, Gold A, Schnoll R, Blendy JA. Translational research in nicotine dependence. Cold Spring Harb Perspect Med 2013;3:a012153
152. Mackey C. Nicotine dependence treatment, DMKC0075633. Datamonitor Healthcare. Datamonitor America, New York; 2012
153. D'Souza MS, Markou A. Neuronal mechanisms underlying development of nicotine dependence: Implications for novel smoking-cessation treatments. Addict Sci Clin Pract 2011;6:4-16
154. Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 2012(8):CD007072
155. Benowitz NL, Goniewicz ML. The regulatory challenge of electronic cigarettes. JAMA 2013;310:685-6
156. Elliott V. Despite ACA mandate, tobacco cessation not always covered. American Medical News. 2012.Available from: Http://www. amednews.com/article/ 20121217/business/121219969/4/ [Last Accessed 4 January 2014]
157. Ponder P, Jefferson A-M, Backinger C, Grana R. Tobacco-related research funding at the National Cancer Institute: Portfolio analysis, fiscal year 2003. Nicotine Tob Res 2007;9:1053-7
158. Klee EW, Ebbert JO, Schneider H, et al. Zebrafish for the study of the biological effects of nicotine. Nicotine Tob Res 2011;13:301-12
159. Beronio K, Po R, Glied S; ASPE ISSUE BRIEF. Affordable Care Act Expands Mental Health and Substance Use Disorder Benefits and Federal Parity Protections for 62 Million Americans. US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. 2013. Available from: Http://aspe.hhs.gov/health/reports/2013/mental/rb-mental. cfm [Last Accessed 4 January 2014]